Expertise in
5
conditions

Dr. Paul P. Cook

East Carolina University
Greenville, NC
Expertise in
5
conditions
Specialties:Infectious Disease
Accepting New Patients
Offers Telehealth
43 Years of Experience
Expertise in
5
conditions
OverviewInsuranceLocationsClinical Research

Overview

Paul Cook is an Infectious Disease provider in Greenville, North Carolina. Dr. Cook has been practicing medicine for over 43 years is highly rated in 5 conditions, according to our data. His top areas of expertise are HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex. Dr. Cook is currently accepting new patients.

His clinical research consists of co-authoring 32 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1982
Specialties
Infectious Disease
Licenses
Internal Medicine in NC
Hospital Affiliations
Ecu Health Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Friday Health
  •  UnitedHealthcare

Locations

EAST CAROLINA UNIVERSITY
2100 Stantonsburg Rd, Greenville, NC 27834
252-209-3000
Other Locations
EAST CAROLINA UNIVERSITY
E 5th St, Greenville, NC 27858
EAST CAROLINA UNIVERSITY
628 E 12th St, Washington, NC 27889
252-975-4319
EAST CAROLINA UNIVERSITY
600 Moye Blvd, Greenville, NC 27834
252-847-7732
EAST CAROLINA UNIVERSITY
2390 Hemby Ln, Greenville, NC 27834
252-744-4500

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
Enrollment Status: Completed
Publish Date: July 28, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19
A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19
Enrollment Status: Completed
Publish Date: November 12, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19
A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19
Enrollment Status: Terminated
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
Enrollment Status: Completed
Publish Date: March 11, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci
Enrollment Status: Completed
Publish Date: January 05, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

32 Total Publications

Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.
Journal: Infectious diseases and therapy
Published: August 30, 2024
Similar Doctors
Expertise in
10
conditions
Dr. Thomas R. Gallaher
Infectious Disease | Emergency Medicine
Expertise in
10
conditions
Dr. Thomas R. Gallaher
Infectious Disease | Emergency Medicine

Vidant Medical Group LLC

500 Academy St S, Vidant Roanoke Chowan Hospitalists, 
Ahoskie, NC 
 (52.2 mi)
252-209-3708
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Gallaher is an Infectious Disease specialist and an Emergency Medicine provider in Ahoskie, North Carolina. Dr. Gallaher is highly rated in 10 conditions, according to our data. His top areas of expertise are Osteomyelitis, Osteomyelitis in Children, Cellulitis, and Methicillin-Resistant Staphylococcus Aureus (MRSA). Dr. Gallaher is currently accepting new patients.

Expertise in
11
conditions
Dr. Octavio Cieza
Infectious Disease
Expertise in
11
conditions
Dr. Octavio Cieza
Infectious Disease

Unc Physicians Network LLC

507 N Brightleaf Blvd, Suite 201, 
Smithfield, NC 
 (52.7 mi)
919-934-8544
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Octavio Cieza is an Infectious Disease provider in Smithfield, North Carolina. Dr. Cieza is highly rated in 11 conditions, according to our data. His top areas of expertise are Osteomyelitis, Osteomyelitis in Children, Cellulitis, and Lymphangitis. Dr. Cieza is currently accepting new patients.

Expertise in
4
conditions
Dr. Alexandra T. Stang
Infectious Disease
Expertise in
4
conditions
Dr. Alexandra T. Stang
Infectious Disease

East Carolina University

2390 Hemby Ln, 
Greenville, NC 
 (0.4 mi)
252-744-4500
Experience:
14+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexandra Stang is an Infectious Disease provider in Greenville, North Carolina. Dr. Stang has been practicing medicine for over 14 years is highly rated in 4 conditions, according to our data. Her top areas of expertise are HIV/AIDS, Myelitis, AIDS Dementia Complex, and AIDS Dysmorphic Syndrome. Dr. Stang is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile